FIELD: medicine.
SUBSTANCE: group of inventions relates to the field of medicine, in particular, to the use of a combination or composition of obinutuzumab with an CD79b antibody-drug conjugate, which is an anti-CD79b-MC-vc-PAB-MMAE, for the treatment of cancer, wherein the anti-CD79b antibody in said conjugate is huMA79b.v28 comprising a light chain variable domain of SEQ ID NO: 69 and the heavy chain variable domain of SEQ ID NO: 70. In one embodiment, the cancer is a CD20 expressing cancer, in particular lymphoma or lymphocytic leukemia.
EFFECT: inventions provide an enhanced antiproliferative effect in the treatment of cancer.
6 cl, 12 dwg, 6 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINED THERAPY BASED ON AFUCOSYLATED CD20 ANTIBODY IN COMBINATION WITH CD22 ANTIBODY CONJUGATE - DRUG PREPARATION | 2014 |
|
RU2700092C2 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2009 |
|
RU2553566C2 |
| ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS FOR USING THEM | 2008 |
|
RU2511410C2 |
| ANTI-CD79B ANTIBODIES, IMMUNOCONJUGATES AND METHODS FOR THEIR USE | 2019 |
|
RU2791984C2 |
| HUMANISED ANTIBODIES AGAINST CD79b AND IMMUNOCONJUGATES AND METHODS OF APPLICATION | 2008 |
|
RU2557319C2 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND METHODS OF USING | 2014 |
|
RU2718990C1 |
| ANTIBODIES TO ALPHA-SYNUCLEIN AND METHODS OF USING | 2014 |
|
RU2697098C1 |
| STABLE COMPOSITIONS OF IMMUNOCONJUGATES CONTAINING ANTIBODIES TO CD79b | 2019 |
|
RU2800803C2 |
| THEOPHYLLINE ANTIBODIES AND METHODS FOR THEIR APPLICATION | 2013 |
|
RU2630664C2 |
| ANTIBODIES AGAINST CD79b, DRUG CONJUGATES AND THEIR USE | 2019 |
|
RU2805251C2 |
